Table 4.
Kaplan–Meier survival analysis based on different subgroups
| ccRCC tissue | Normal tissue | n (%) | MST (months) | OS (%) | c2 | 95% CI | Sig. (P-value) |
|---|---|---|---|---|---|---|---|
| Nrf2 | 152 | ||||||
| Low | – | 106 (69.7) | 78.55±1.072 | 91.7 | 4.127 | 76.445–80.647 | 0.042* |
| High | – | 46 (30.3) | 76.88±2.722 | 88.2 | 71.547–82.217 | ||
| HO-1 | 133 | ||||||
| Low | – | 59 (44.4) | 80.28±0.716 | 98.1 | 4.846 | 78.875–81.680 | 0.028* |
| High | – | 74 (55.6) | 76.39±1.456 | 93.1 | 70.799–81.988 | ||
| Nrf2 | Nrf2 | 149 | |||||
| High | Positive | 131 (87.9) | 80.91±1.151 | 95 | 8.029 | 78.651–83.164 | 0.005** |
| Low | Positive | ||||||
| Low | Negative | ||||||
| High | Negative | 18 (12.1) | 62.65±4.249 | 76.9 | 54.322–70.977 | ||
| HO-1 | HO-1 | 119 | |||||
| High | Positive | 105 (88.2) | 81.90±1.044 | 94.5 | 9.601 | 79.856–83.947 | 0.002** |
| Low | Positive | ||||||
| Low | Negative | ||||||
| High | Positive | 14 (11.8) | 58.59±3.824 | 76.2 | 51.101–66.090 | ||
| Nrf2 | Nrf2 | 149 | |||||
| High | Positive | 91 (61.1) | 77.75±1.903 | 94.2 | 4.040 | 74.017–81.476 | 0.044* |
| High | Negative | ||||||
| Low | Negative | ||||||
| Low | Positive | 58 (38.9) | 80.19±0.803 | 98.3 | 78.615–81.764 | ||
| HO-1 | HO-1 | 119 | |||||
| High | Positive | 84 (70.6) | 80.15±1.520 | 93.4 | 0.778 | 77.165–83.125 | 0.378 |
| High | Negative | ||||||
| Low | Negative | ||||||
| Low | Positive | 35 (29.4) | 79.78±1.200 | 96.9 | 77.430–82.132 |
Note:
*
P<0.05;
**
P<0.01.
Abbreviations: ccRCC, clear cell renal cell carcinoma; high (expression), moderate and strong positive; low (expression), negative and weak positive; MST, mean survival time; OS, overall survival; sig., significance.